Archiv der Pharmazie · 2016 · 31 citations · 19 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular OncologyOncology PharmacologyStructure-activity Relationship AnalysisTyrosine Kinase InhibitorsEgfr InhibitionEpidermal Growth Factor Receptor InhibitionHer2 InhibitorsKinase InhibitorsProtein Kinase InhibitorsPyrimidine AnalogsPyrimidine AnaloguesPyrimidine Chemistry
Dual inhibition of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER‐2) is an attractive cancer therapeutic approach. In this study, new series of 4‐anilinothieno[2,3‐ d ]pyrimidines were designed, synthesized, and tested as dual EGFR/HER‐2 kinase inhibitors. Five compounds ( 8a , 8b , 8e–g ) demonstrated low to submicromolar inhibition of both kinases with IC 50 values of 1.2, 0.6, 0.3, 0.2, 0.4 μM and 8.2, 3.4, 1.3, 0.5, 2.7 μM for the EGFR and HER‐2, respectively. Introduction of a 5,6‐tetramethylene moiety into the thienopyrimidine core bearing a 4‐(3‐fluorobenzyloxy)‐3‐chloroaniline tail resulted in a favorable increase in both the EGFR and HER‐2 inhibitory activities. Compound 8f (IC 50 EGFR/HER‐2: 0.2/0.5 μM) also exhibited significant cell growth inhibition on some specific NCI cell lines, especially ovarian, breast, non‐small‐cell lung cancer, and renal cancer cell lines.
19
Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
Valentina Cappello, Laura Marchetti, Paola Parlanti et al. · Scientific Reports · 2016 · 13.3K citations · Full text
Medicine, Neurobiology, Neuroscience +17
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Edgar R. Wood, Anne T. Truesdale, Octerloney B. McDonald et al. · Cancer Research · 2004 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +14